Charles River Laboratories International (CRL) Cash & Equivalents (2009 - 2025)

Charles River Laboratories International (CRL) has reported Cash & Equivalents for 17 consecutive years, with $213.8 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Cash & Equivalents rose 9.85% year-over-year to $213.8 million; the TTM figure through Dec 2025 stood at $213.8 million (up 9.85% YoY), while the FY2025 annual figure was $213.8 million, up 9.85% from the prior year.
• Cash & Equivalents came in at $213.8 million for Q4 2025 at Charles River Laboratories International, up from $207.1 million in the prior quarter.
• The five-year high for Cash & Equivalents was $465.4 million in Q1 2021, with the low at $157.2 million in Q3 2023.
• Average Cash & Equivalents over 5 years is $229.6 million, with a median of $211.4 million recorded in 2021.
• Across the five-year window, Cash & Equivalents plunged 48.03% in 2022 and jumped 62.23% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $241.2 million in 2021, then declined by 3.03% to $233.9 million in 2022, then grew by 18.32% to $276.8 million in 2023, then fell by 29.69% to $194.6 million in 2024, then grew by 9.85% to $213.8 million in 2025.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $213.8 million, $207.1 million, and $182.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.